PDCD1 and non-small cell lung carcinoma: The success of monoclonal antibodies targeting the inhibitory receptor programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) has changed the therapeutic landscape of advanced stage non-small cell lung cancer (NSCLC).